RO4929097 in Treating Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well RO4929097 works in treating patients with metastatic
colorectal cancer. RO4929097 may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.